09:44 AM EDT, 03/26/2024 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) said Tuesday that the Japanese Ministry of Health, Labor and Welfare has approved Adzynma to treat congenital thrombotic thrombocytopenic purpura, a rare blood clotting disorder, in patients 12 years old and older.

The approval was based on the company's data from an interim analysis of efficacy, pharmacokinetic, safety and tolerability in a crossover phase 3 trial in patients ages 12 to 68, Takeda said.

The company said the approval would not affect its consolidated forecast for the current fiscal year ending March 31.

Shares of the company were up 1.8% in early Tuesday trading.

Price: 14.40, Change: +0.25, Percent Change: +1.77